Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Epizyme's Sarcoma Drug Tazverik

By Brian Orelli, PhD - Jan 23, 2020 at 7:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The accelerated approval will need to be confirmed by an ongoing clinical trial in previously untreated patients.

Epizyme (EPZM -5.09%) secured an accelerated approval from the Food and Drug Administration for its sarcoma drug Tazverik. The drug was approved specifically for patients with metastatic or locally advanced epithelioid sarcoma who aren't eligible for surgery to completely remove the tumor.

Tazverik is the first FDA-approved drug for epithelioid sarcoma. It's also the first FDA-approved drug that targets enhancer of zeste homolog 2 (EZH2), a protein involved in modifying DNA, which leads to the suppression of expression of certain genes, including tumor suppressor genes. By inhibiting EZH2, Tazverik reduces the DNA modification, thereby increasing the expression of tumor suppressors that can slow or stop growth of cancerous cells.

Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

In the phase 2 clinical trial used as a basis for the approval, 15% of patients responded to the drug, including 1.6% of patients who had a complete response. While a 15% response rate is rather low, most of the patients had a prior surgery and/or chemotherapy before entering the clinical trial, so their options were limited -- as noted, there aren't any approved therapies for this type of cancer.

Since Epizyme received an accelerated approval based on a mid-stage trial, the biotech will need to verify the results with a confirmatory study. Epizyme has already started the study that's comparing Tazverik plus the chemotherapy doxorubicin to doxorubicin alone in epithelioid sarcoma patients who were previously untreated. In addition to securing full approval, the confirmatory trial could be used as the basis for an additional approval in the first-line treatment, expanding the potential market for Tazverik.

Epizyme expects Tazverik to be available to patients within 10 business days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Epizyme Stock Quote
Epizyme
EPZM
$0.48 (-5.09%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.